{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:02:19Z","timestamp":1720108939082},"reference-count":82,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.amjcard.2009.09.016","type":"journal-article","created":{"date-parts":[[2009,11,5]],"date-time":"2009-11-05T12:30:55Z","timestamp":1257424255000},"page":"22E-31E","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S","title":["The Genetics of High-Density Lipoprotein Metabolism: Clinical Relevance for Therapeutic Approaches"],"prefix":"10.1016","volume":"104","author":[{"given":"Aart C.","family":"Strang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.09.016_bib1","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2008.10.016","article-title":"Prevention and treatment of atherosclerosis: a practitioner's guide for 2008","volume":"122","author":"Lewis","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacc.2003.08.061","article-title":"Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update","volume":"43","author":"Gotto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.09.016_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein\u2014the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid\u2014a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2009.09.016_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/MOL.0b013e328306a043","article-title":"The value of HDL genetics","volume":"19","author":"Holleboom","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9150(01)00447-6","article-title":"The impact of phospholipid transfer protein (PLTP) on HDL metabolism","volume":"155","author":"Huuskonen","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2009.09.016_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.amjcard.2009.09.016_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.mol.0000162318.47172.ef","article-title":"Inherited disorders of HDL metabolism and atherosclerosis","volume":"16","author":"Hovingh","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/HCO.0b013e3281a8acad","article-title":"Genetic determinants of HDL: monogenic disorders and contributions to variation","volume":"22","author":"Klos","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib11","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1074\/jbc.M609336200","article-title":"A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux","volume":"282","author":"Favari","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2009.09.016_bib12","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/bi011716p","article-title":"Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I","volume":"41","author":"Bielicki","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.amjcard.2009.09.016_bib13","first-page":"1083","article-title":"AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission","volume":"37","author":"Gualandri","year":"1985","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjcard.2009.09.016_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.016_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2004.06.070","article-title":"A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease","volume":"44","author":"Hovingh","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.ATV.18.8.1242","article-title":"Apolipoprotein A-I(Zavalla) (Leu159\u2013>Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease","volume":"18","author":"Miller","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1161\/01.ATV.16.12.1416","article-title":"A cysteine-containing truncated apo A-I variant associated with HDL deficiency","volume":"16","author":"Moriyama","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0021-9150(00)00555-4","article-title":"Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-I(Zaragoza) (L144R)","volume":"154","author":"Recalde","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2009.09.016_bib19","doi-asserted-by":"crossref","first-page":"S_371","DOI":"10.1161\/circ.118.suppl_18.S_371-a","article-title":"Compound RVX-208 modulates HDL-C levels and function in non-human primates and in early (phase I) human trials","volume":"118","author":"Krimbou","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.016_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/HCO.0b013e3283007ccd","article-title":"Acute effects of high-density lipoproteins: biochemical basis and clinical findings","volume":"23","author":"Chiesa","year":"2008","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","article-title":"Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans","volume":"100","author":"Eriksson","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.016_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0022-2275(20)32212-4","article-title":"Intravenous apoA-I\/lecithin discs increase pre-\u03b2-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans","volume":"42","author":"Nanjee","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib23","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.09.016_bib24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.09.016_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.016_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11883-009-0008-8","article-title":"Apolipoprotein A-I mimetic peptides","volume":"11","author":"Van Lenten","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2009.09.016_bib27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients","volume":"49","author":"Bloedon","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1567-5688(08)70007-2","article-title":"RVX-208: A small molecule that increases ApoA-I, HDL-C, and cholesterol efflux","volume":"9","author":"Jahagirdar","year":"2008","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.amjcard.2009.09.016_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1194\/jlr.M400438-JLR200","article-title":"Phosphatidylinositol increases HDL-C levels in humans","volume":"46","author":"Burgess","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-2275(20)43114-1","article-title":"The plasma lecithins: cholesterol acyltransferase reaction","volume":"9","author":"Glomset","year":"1968","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/11905","article-title":"Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency","volume":"22","author":"Brooks-Wilson","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjcard.2009.09.016_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.nutr.26.061505.111214","article-title":"Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis","volume":"26","author":"Brunham","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.amjcard.2009.09.016_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/3-540-27661-0_20","article-title":"Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport","author":"Hersberger","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib34","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1172\/JCI200112810","article-title":"Monocyte\/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels","volume":"108","author":"Haghpassand","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.016_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(02)07277-X","article-title":"Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study","volume":"359","author":"van Dam","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.09.016_bib36","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.289.5484.1524","article-title":"Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers","volume":"289","author":"Repa","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2009.09.016_bib37","doi-asserted-by":"crossref","first-page":"37735","DOI":"10.1074\/jbc.R100035200","article-title":"Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism","volume":"276","author":"Lu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2009.09.016_bib38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1194\/jlr.M300450-JLR200","article-title":"Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator","volume":"45","author":"Miao","year":"2004","journal-title":"J Lipid Res"},{"issue":"suppl","key":"10.1016\/j.amjcard.2009.09.016_bib39","doi-asserted-by":"crossref","first-page":"n15","DOI":"10.1016\/j.amjcard.2007.08.008","article-title":"Liver X receptor and farnesoid X receptor as therapeutic targets","volume":"100","author":"Rader","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurheartj\/ehl392","article-title":"Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease","volume":"28","author":"Shah","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2009.09.016_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9150(85)90064-4","article-title":"Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia","volume":"58","author":"Koizumi","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2009.09.016_bib43","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib44","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1172\/JCI117537","article-title":"Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol","volume":"94","author":"Inazu","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.016_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MOL.0b013e32803dbdd6","article-title":"Genetic factors affecting HDL levels, structure, metabolism and function","volume":"18","author":"Sviridov","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib46","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.016_bib47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1194\/jlr.M300520-JLR200","article-title":"A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly","volume":"45","author":"Curb","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1006\/pmed.1998.0340","article-title":"A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency","volume":"27","author":"Moriyama","year":"1998","journal-title":"Prev Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.CIR.0000153341.46271.40","article-title":"Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects","volume":"111","author":"Boekholdt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.09.016_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2007.11.019","article-title":"High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants","volume":"200","author":"van Acker","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2009.09.016_bib51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-2275(20)33876-1","article-title":"Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia","volume":"39","author":"Bruce","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib52","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2009.09.016_bib53","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib54","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib55","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjcard.2009.09.016_bib56","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib57","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"de Grooth","year":"2002","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2009.09.016_bib58","first-page":"A322","article-title":"Absence of effect of R1658\/JTT-705 on blood pressure and tissue expression of renin-angiotensin system related genes in rats [abstract]","volume":"51","author":"Stroes","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib59","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2009.09.016_bib60","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/7766","article-title":"A novel endothelial-derived lipase that modulates HDL metabolism","volume":"21","author":"Jaye","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjcard.2009.09.016_bib61","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1194\/jlr.P600002-JLR200","article-title":"Endothelial lipase is associated with inflammation in humans","volume":"47","author":"Paradis","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1172\/JCI16306","article-title":"Endothelial lipase is a major determinant of HDL level","volume":"111","author":"Ishida","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.016_bib63","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehp145","article-title":"The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations","volume":"30","author":"Jensen","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2009.09.016_bib64","first-page":"1042","article-title":"Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans","volume":"119","author":"Edmondson","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2009.09.016_bib65","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1074\/jbc.272.7.3953","article-title":"Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion","volume":"272","author":"Rye","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2009.09.016_bib66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2007.04.046","article-title":"Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis","volume":"196","author":"Schgoer","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2009.09.016_bib67","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/01.ATV.0000094433.98445.7F","article-title":"High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease","volume":"23","author":"Schlitt","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib68","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1194\/jlr.M800414-JLR200","article-title":"PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study","volume":"50","author":"Schlitt","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00125-005-0088-0","article-title":"Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus","volume":"49","author":"de Vries","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2009.09.016_bib70","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.metabol.2008.07.031","article-title":"Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia","volume":"57","author":"Engler","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2009.09.016_bib71","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/ATVBAHA.106.137646","article-title":"Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects","volume":"27","author":"Kiss","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2009.09.016_bib72","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1006\/bbrc.1999.1597","article-title":"DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate","volume":"264","author":"Tu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.amjcard.2009.09.016_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.1995.tb01220.x","article-title":"Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients","volume":"238","author":"Kahri","year":"1995","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1388-1981(00)00153-0","article-title":"Lecithin cholesterol acyltransferase","volume":"1529","author":"Jonas","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.amjcard.2009.09.016_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-2275(20)37433-2","article-title":"The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes","volume":"38","author":"Kuivenhoven","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2009.09.016_bib76","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbrc.2004.03.177","article-title":"Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease","volume":"318","author":"Zhang","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.amjcard.2009.09.016_bib77","unstructured":"Krause BR. The Use Of LCAT Infusion To Treat Acute Coronary Syndromes. National Institutes of Health. 1\u20139-2008. 1\u20136-2009. Ref Type: Online Source."},{"key":"10.1016\/j.amjcard.2009.09.016_bib78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.metabol.2008.11.019","article-title":"Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein","volume":"58","author":"Amar","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2009.09.016_bib79","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib80","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.09.016_bib81","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng.291","article-title":"Common variants at 30 loci contribute to polygenic dyslipidemia","volume":"41","author":"Kathiresan","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjcard.2009.09.016_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909023777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909023777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T11:22:21Z","timestamp":1634124141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914909023777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0002914909023777"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.09.016","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}